Background: Age related declines in walking performance may be partly attributable to skeletal
INTRODUCTION
Walking performance decreases significantly with age, but with considerable individual variation (1) . The underlying causes of age-related slowing are of great interest as slower gait is an independent risk factor for institutionalization (2) and mortality (3) . The role of skeletal muscle in slowing walking performance is still unclear, as sarcopenia only modestly predicts mobility maintenance (or loss) in older adults (4) . Further, maximum aerobic capacity (VO 2 peak) decreases with age independent of lean mass and physical activity levels (5). VO 2 peak is partly dependent on the ability of skeletal muscle mitochondria to produce adenosine triphosphate (ATP) and mitochondria produce over 90% of ATP needed for movement (6). The capacity for mitochondrial oxidative phosphorylation is lower in aged compared to younger skeletal muscle, as both mitochondrial function and content are reduced (7) (8) . However, this age associated decrease in mitochondrial content and function may also be due in part to reduced physical activity and not completely attributable to aging per se (9) . Thus, lower mitochondrial function may play a role in the age-related slowing of gait speed.
In fact, worse skeletal muscle mitochondrial function in older adults has been linked with higher fatigability (10) , lower physical function (11) and slower gait speed (12). For example, Coen et al. showed that higher mitochondrial function was significantly associated with faster gait speed in higher functioning older adults (13) . However, the relationship between mitochondrial function and walking performance has not been examined in older adults with both high and low levels of physical function. The purpose of this research was to examine the cross-sectional relationship between mitochondrial energetics, measured by 31 P magnetic resonance spectroscopy (MRS), and walking performance in older adults with a wide range of functional capacity.
METHODS

Participants
Participants were from two studies, employing identical measures of mobility and mitochondrial capacity for oxidative phosphorylation. The higher functioning cohort was from the Study of Energy in Aging-Pilot (SEA) (10, 13) and lower functioning participants were from an ancillary study to the Lifestyle Interventions and Independence for Elders (LIFE) Study (14).
SEA participants were community-dwelling (n = 37) men and women aged 70-89 years from the Pittsburgh, PA area and inclusion and exclusion criteria have been described in detail elsewhere (10, 13) . Briefly, inclusion criteria included body mass index 20-32kg/m 2 , ability to walk without an assistive device and free of basic activities of daily living disability. Exclusion criteria included history of hip fracture, heart attack, angioplasty, or heart surgery within the past 3 months, cerebral hemorrhage within the past 6 months, stroke within the past 12 months, or symptomatic cardiovascular or pulmonary disease. Participants were assessed at the magnetic resonance imaging (MRI) center for 31 P MRS scan eligibility for ability to lie in a supine position for 1-hour, no MR unsafe metal or other implants, bilateral joint replacements, and tattoos. The final analytical sample from SEA included 29 participants with complete MRS and 400m walk data.
The LIFE Study was a multi-center randomized controlled trial designed to test the effectiveness of physical activity compared with health education on preventing mobility disability (14-15 Both LIFE and SEA study protocols were approved by the University of Pittsburgh Institutional Review Board. All participants provided written informed consent.
Clinic Examination and Measurements
Participants completed clinic visits at the Health Studies Research Center at the University of Pittsburgh. Body height (cm) was measured using a wall-mounted stadiometer and body weight (kg) with a standard certified, calibrated scale, and used to calculate BMI (kg/(m 2 ).
Participants completed demographic and self-reported health questionnaires. Questions were phrased in a similar manner between studies with one exception: history of arthritis. In SEA, the question asked about any history of arthritis, whereas LIFE asked about a doctor's visit in the past 6-months for arthritis or rheumatism. Diabetes was defined as either self-reported diagnosis, use of diabetic hypoglycemic medication or fasting blood glucose ≥126 mg/dL.
Lower extremity function was assessed using the SPPB, a widely used performance measure scored on a 0-12 point scale. The test includes 3 parts: a 4m walk; 5 timed, repeated chair stands; and a balance battery each worth 0-4 points (16). Seven-day free-living physical activity was measured in both studies; LIFE used the Actigraph™ accelerometer (model GT3X, ActiGraph, LLC), while SEA employed the SenseWear™ Pro armband (BodyMedia, Pittsburgh, PA). NHANES cut-points (17) were used to categorize Actigraph counts, while the Sensewear's
proprietary algorithm was used to calculate minutes per day spent in moderate and above (≥3METs) intensity activities.
400-Meter Walk
Walk protocols for both studies were nearly identical (13-14). The only difference was that LIFE permitted use of a single pronged cane. In both studies the test was conducted on a level ground 20-meter course. Participants were instructed to walk at their usual pace, without overexertion for 10 laps (20m up and back). Following the walk, participants from both studies were asked "Is anything bothering you?" and reported symptoms were recorded. Discomfort following the walk was defined as responding yes to this question. One SEA participant of the original 37 was excluded from analyses due to not completing the 400m walk.
Determination of ATP max by 31 P MRS
MRS protocols were identical and both studies utilized the same MR magnet, technician and MRS analyst. Phosphocreatine (PCr) recovery after exercise (ATPmax) was used to quantify mitochondrial capacity for oxidative phosphorylation. 31 P MRS has been validated by animal and human studies showing that ATPmax varies in direct proportion to oxidative enzyme activity of healthy muscle (18) and mitochondrial content in human muscle (7) . ATPmax has good reproducibility illustrated by previously published Bland Altman analysis from SEA (19) .
The exercise protocol was performed in an MRI magnet (3T TIM Trio, Siemens' Medical System) (10, 13) . Participants laid supine with the right knee (unless contraindicated) elevated at ~30º. Straps were placed over the legs and a 2.5" surface RF coil tuned to 31 P was placed over the quadriceps. Participants performed repeated voluntary, rapid, maximal isometric contractions (kicking) for two bouts (30s and 36s) followed by a 6-minute rest. The protocol was designed to deplete PCr by 33-66% without inducing acidosis (pH <6.8). A monoexponential fit of [PCr] recovery yields the recovery constant (k) for use in calculating ATP max :
Previous analyses of human vastus lateralis muscle biopsies revealed that ATP content accounted for the range of PCr/ATP levels among participants aged 65-80 years (7). In contrast, PCr was stable (as was total creatine) and averaged 27mM. Thus, we used 27mM for [PCr] rest (10, 13) .
Finally, we determined pH from the chemical shift of the Pi peak relative to the PCr peak (20) .
Statistical Analyses
The final analytic sample included 29 SEA and 33 LIFE participants with complete ATPmax and 400m data (total n=62). Baseline characteristics, means and standard deviations for continuous variables and frequencies and percents for categorical variables, were generated for each study. To test for between study differences, Wilcoxon rank-sum, chi-squared and Fischer's exact tests were used where appropriate.
To determine the relationship between ATPmax and 400m walk time (s) multivariable linear regression was used. We present results for each group separately. Bivariate and multivariable models adjusted for age, sex, race, study and BMI were generated. The beta coefficients represent the difference in 400m walk time (in seconds) per 1 SD higher ATPmax (0.14 mM atp/s). Since it is has been shown that those with type 2 diabetes have impaired mitochondrial function(21), we also examined the effect of diabetes on the relationship between ATPmax and 400m walk time. Physical activity was considered last because it is a known determinant of muitochondrial function, as we have previously shown (13, 22) . All analyses were performed with SAS version 9.3.
RESULTS
Baseline Comparison of SEA and LIFE Study Participants
LIFE compared with SEA participants were significantly more overweight, less active, had lower SPPB scores, and slower 400m walk times (Table 1) . Of note, only one SEA participant had an SPPB score <9, an inclusion criteria for LIFE. LIFE also contained a significantly larger proportion of females and African Americans as well as a higher prevalence of diabetes and fewer reporting consuming 6 or more drinks per (Table 1) . Despite significantly lower physical function and activity levels, LIFE had similar ATPmax compared with SEA (0.55 ± 0.14 vs. 0.52 ± 0.14mM ATP/s, p = 0.31). and foot pain, while 1 requested their straight cane due to general discomfort. In SEA, the 5 participants who reported discomfort reported the following symptoms: shortness of breath and back pain, knee and calf pain, back pain, hip and calf pain, and foot pain.
Relationship between ATPmax and 400m Walk Time
Higher levels of ATPmax were significantly related to faster 400m walk time in SEA (ß = -29.3, p = 0.02), with ATPmax explaining 19% of the variance in walk time (Table 2, Figure   1 ). However, no association was observed in LIFE (ß = 6.2, p = 0.74, Table 2, Figure 1 ). After adjustment for age, sex, race and BMI, the relationship between ATPmax and 400m walk time in the SEA was attenuated slightly (ß = -24.8, p = 0.08). Adding diabetes to the fully adjusted models had no effect on the relationship between ATPmax and walk time (SEA: p = 0.95; LIFE: 
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ATPmax is defined as phosphocreatine recovery in the quadriceps following an acute bout of exercise measured by 31 
DISCUSSION
High ATPmax was associated with faster time to walk 400m in higher functioning, active SEA participants, but not lower functioning, sedentary LIFE participants. This lack of an association is contrary to hypotheses generated from our previous work (13) as well as several other studies of older adults (11) (12) 23) . Namely, higher mitochondrial function measured by 31 P MRS was related to faster time to complete a get-up-and-go-test in French, lower functioning hospitalized (n=49, aged 86.1 ± 5.3 years) and higher functioning community-dwelling older adults (n=28, aged 74.5 ± 6.2 years) (12). Similarly, a muscle biopsy study in relatively younger (aged 62.0 ± 11.8) peripheral artery disease patients showed that higher mitochondrial function was related to longer walking time during a VO 2 max test (23) . Importantly, both of the previously mentioned studies measured mitochondrial function in the gastrocnemius muscle (12,23), whereas the current study used the quadriceps. The conflicting results could be attributable to studying different muscle groups, as previous cross-sectional work suggests aging may affect locomotory muscles differently (24). However, the vastus lateralis (VL) muscle, the muscle of interest in the current study, may be more susceptible to age and physical activity related changes compared to the tibialis anterior muscle (24). Therefore, in theory the VL muscle would have been more closely associated with age related decreases in walking performance. The inconsistencies concerning the relationship between ATPmax and walking performance could be attributable to our walking performance measure (400m walk); however, lower functioning individuals walk closer to their maximal performance during a usual paced 400m walk compared with higher functioning (26) . Therefore, since ATPmax is highly related to VO 2 peak (13), a stronger relationship would have been expected in the lower functioning LIFE participants. Unless the LIFE participants had other impairments limiting walking performance, unrelated to oxidative capacity of the quadriceps, such as pain or joint stiffness. Indeed, although the difference did not reach statistical significant, over twice the proportion of LIFE participants reported discomfort, mainly due to pain, during the walk compared with SEA (36% vs. 17%).
There are several possible explanations for why ATPmax was unrelated to 400m walk time in lower functioning participants. First, there may be differences in muscle mass that could affect walking time independent of ATPmax; however LIFE was lacking a measure of muscle mass. The, the higher prevalence of discomfort and pain experience by LIFE participants during the walk may have caused them to slow down for reasons unrelated to mitochondrial function.
Joint impairments (27) , arthritis (28) , knee (29) and back pain (30) are associated with slower walking speed or physical disability in older adults. Secondly, the LIFE Study was lacking a measure of mitochondrial efficiency (P/O), which is related to exercise efficiency in older adults (31) . Finally, since discomfort and pain may evoke alterations to normal gait (32) , it is plausible that those with both higher levels of ATPmax and slower walk times were biomechanically inefficient. Thus, these participants may be producing more energy (ATP) to walk at the same speed (or more slowly) than a biomechanically efficient individual. Indeed, higher energy cost of walking (VO 2 normalized to gait speed) is related to worse biomechanical gait parameters (33) (34) and impaired mobility (34) (35) (36) . This may cause a less biomechanically efficient individual to have a higher ATPmax than their activity level or walking speed would suggest, which may also partially explain the phenomenon of similar ATPmax levels observed in SEA compared with LIFE. However, we cannot rule out the mediating role of other factors related to VO 2 peak such as cardiopulmonary function. Further investigations are needed, particularly in lower functioning older adults, to further understand the interrelationships between ATPmax, gait biomechanics, energy cost of walking and walking performance.
Strengths of this study include a larger sample size compared with previous work examining the relationship between skeletal muscle mitochondrial energetics and walking performance in older adults and including a diverse population in terms of sex, race, function and physical activity levels. Mitochondrial function was measured directly and in vivo using 31 P MRS. Performance measures, as opposed to self-report, were used to quantify physical function and walking speed. Limitations include participants being from two separate studies; however, the study sites, primary outcome and predictor were identical. Muscle biopsies were not obtained in the LIFE cohort, so mitochondrial efficiency and other parameters could not be determined.
The study was cross-sectional, thus no causal inferences can be made. Despite being the largest study to have examined these relationships to date, the sample size was still relatively small, which limited our ability to stratify by possible mediating/confounding factors, particularly those that differed across the study populations, or test for interactions.
In conclusion, our study provides important and novel insights into the role of skeletal muscle mitochondrial capacity for oxidative phosphorylation in walking performance in older adults. Specifically, ATPmax (functional oxidative capacity of the quadriceps) was unrelated to walking times in lower functioning, sedentary participants and those with a wide range of function. However, higher mitochondrial function was related to faster walking times in higher functioning, active participants. This suggests that lower mitochondrial function may be a marker of early functional decline in higher functioning older adults. Further, mitochondrial function does not appear to be a limiting factor in lower functioning participants, who may slow for other reasons such as pain while ambulating. Larger studies examining other aspects mitochondrial energetics, energy cost and physical performance in older adults with wide age (e.g. aged 50-85) and physical function ranges are needed to further investigate these relationships.
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